Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Chabanon

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
International Journal of Antimicrobial Agents|August 16, 2006
Increased amikacin dosage requirements in burn patients receiving a once-daily regimenJ M Conil, B Georges, A Breden, et al.
Presse Medicale (Paris, France : 1983)|October 26, 1988
[Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France]A Thabaut, J Acar, G Arlet, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 27, 2005
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimenB Georges, J M Conil, P Cougot, et al.
Pathologie-Biologie|July 27, 1999
[Continuous versus intermittent cefepime infusion in critical care. Preliminary results]B Georges, M Archambaud, S Saivin, et al.
Pathologie-Biologie|May 1, 2002
[Importance of a cefpirome-vancomycin combination on bactericidal kinetics in severe MRSA infections in intensive care]B Georges, C Roche, M Archambaud, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
International Journal of Antimicrobial Agents|August 16, 2006
Increased amikacin dosage requirements in burn patients receiving a once-daily regimenJ M Conil, B Georges, A Breden, et al.
Presse Medicale (Paris, France : 1983)|October 26, 1988
[Sensitivity of Pseudomonas aeruginosa and Klebsiella spp. to ceftazidime. Current status in France]A Thabaut, J Acar, G Arlet, et al.
International Journal of Clinical Pharmacology and Therapeutics|August 27, 2005
Cefepime in critically ill patients: continuous infusion vs. an intermittent dosing regimenB Georges, J M Conil, P Cougot, et al.
Pathologie-Biologie|July 27, 1999
[Continuous versus intermittent cefepime infusion in critical care. Preliminary results]B Georges, M Archambaud, S Saivin, et al.
Pathologie-Biologie|May 1, 2002
[Importance of a cefpirome-vancomycin combination on bactericidal kinetics in severe MRSA infections in intensive care]B Georges, C Roche, M Archambaud, et al.
Pageof 5